Hedge Fund Stock Picks & Ticker Coverage
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Baron Health Care Fund Neal Kaufman | “Cytokinetics, Incorporated ($CYTK) is a biopharmaceutical enterprise focused on muscle biology therapies to treat cardiovascular diseases. The manager took a bearish directional move by actively reducing the Fund's holding due to disappointing commercial adoption and newly emerging clinical safety issues. The economic viability of the company's valuation was reliant on aggressive commercial penetration and unit adoption for its lead cardiac drug MYQORZO (aficamten). However, second-quarter commercial sales of only $25 million across approximately 1,500 patients fell far short of market expectations, highlighting slower operational leverage and extended commercial ramp cycles in specialty cardiology markets. Catalysts turned negative following the publication of full ACACIA-HCM clinical trial results in the New England Journal of Medicine, which revealed elevated rates of serious adverse events including heart failure with reduced ejection fraction. Ongoing risks to monitor include the FDA mandating onerous echocardiographic monitoring protocols and strict black-box warnings that could permanently constrain addressable patient volumes.” | BEAR | Q3 2026 Oct 14, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.